TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
Status:
Not yet recruiting
Trial end date:
2033-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to improve upon the TINI study treatment. The study will test
the ability of a type of immunotherapy called blinatumomab to clear persistent leukemia.
Blinatumomab targets CD19 which is located on the leukemia cells outer membrane.